im96 car-t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2022 (NCT05287165)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Heat-stable enterotoxin receptorImmunity, passive
GUCY2C immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06718738 | Phase 1 | Dec 15, 2024 | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University |
| NCT05287165 | Early Phase 1 (Phase 1) | Mar 10, 2022 | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immunochina Medical Science & Technology Co., Ltd. | For profit | 2 | 2 | 1 | 2022 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1